Bladder Cancer
TYTOCARE™ home telemonitoring device after radical cystectomy to optimise postoperative outcomes.
January 3, 2025
Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials.
January 3, 2025
Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer.
January 2, 2025
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer.
January 1, 2025
Does time matter in early radical cystectomy? Comparing outcome, clinical and pathological characteristics of immediate versus deferred radical cystectomy.
December 31, 2024
Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
December 31, 2024
The Financial Burden of Localized and Metastatic Bladder Cancer.
December 30, 2024
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI.
December 27, 2024
PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the bladder.
December 26, 2024
A novel smartphone application for bladder cancer management (BCM App): Design, development, and usability evaluation.
December 26, 2024
Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice.
December 25, 2024
Exploring the Immunoresponse in Bladder Cancer Immunotherapy.
December 25, 2024
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.
December 24, 2024
Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial Carcinoma.
December 24, 2024